Status:
RECRUITING
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Glioma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarize...
Eligibility Criteria
Inclusion
- • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection.
- Ages 18-80, including male and female
- Suitable to undergo contrast-enhanced MRI
- Negative serum pregnancy test
Exclusion
- Inability to undergo MRI scan
- Inability to receive IV contrast secondary to severe reaction or renal insufficiency.
Key Trial Info
Start Date :
August 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04772456
Start Date
August 11 2020
End Date
December 31 2027
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rosy Njonkou Tchoquessi
Baltimore, Maryland, United States, 21201